Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites

Blood

Volumn 96, Issue 10, 2000, Pages 3569-3577

  Riemersma, S A ^a   Jordanova, E S ^a   Schop, R F J ^a   Philippo, K ^a   Looijenga, L H J ^a   Schuuring, E ^a   Kluin, P M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ARTICLE; B CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MAPPING; GENE MUTATION; GENETIC RECOMBINATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERPHASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0034669309     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.10.3569     Document Type: Article

References (60)

1. Cell adhesion receptors in lymphoma dissemination
2. A vision of cell death: Insights into immune privilege
3. Inflammatory cytokines in the brain: Does the CNS shape immune responses?
4. Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy
5. Primary central nervous system lymphoma
6. Primary CNS lymphoma: Findings outside the brain
7. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
8. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
9. T-cell mediated immunotherapy for B-cell lymphoma
10. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
11. HLA and cancer: From research to clinical impact
12. + T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide
13. + cytotoxic T lymphocytes in humans
14. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
15. CD4 T-cells and their role in antitumor immune responses
16. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
17. B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain
18. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma
19. Expression of MHC class II antigens in human B-cell leukemia and non-Hodgkin's lymphoma
20. Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study
21. Successful immunotherapy of an intraocular tumor in mice
22. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression
23. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter
24. Human leukocyte antigen class I gene mutations in cervical cancer
25. The revised European-American lymphoma (REAL) classification
26. Clinical significance of BCL2 and P53 protein expression in diffuse large B-cell lymphoma: A population based study
27. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma
28. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
29. Detection of a novel human class II HLA antigen
30. Distinct HLA-DR epitopes and distinct families of HLA-Dr molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-lak cross-reacting with human DR molecule. I. Cross-inhibition studies of mAB-cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb
31. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in Archival paraffin-embedded tumor samples
32. Microsatellites in the HLA region: 1998 update
33. Allelic loss and prognosis in carcinoma of the uterine cervix
34. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes
35. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization
36. Cytogenetic evolution patterns in non-Hodgkin's lymphoma
37. On the statistical analysis of alleric-loss data
38. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
39. An analysis of variation in the long-range genomic organization of the human major histocompatibility complex class II region by pulsed-field gel electrophoresis
40. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
41. Definition of HLA-C alleres using sequence-specific oligonucleotide probes (PCR-SSOP)
42. HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines
43. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
44. Mechanisms of loss of HLA class I expression on colorectal tumor cells
45. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific
46. Transcriptional suppression of HLA-B expression by c-myc is mediated through the core promoter elements
47. Locus-specific transcriptional control of HLA genes
48. Loss of human leukocyte antigen expression on colorectal tumor cell lines: Implications for anti-tumor immunity and immunotherapy
49. The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression
50. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course
51. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T-cells to mutant cells that have decreased expression of class II antigens
52. Complete sequence gene map of a human major histocompatibility complex. The MHC Sequencing consortium
53. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
54. + T-cell help
55. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation
56. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T-cells
57. Primary central nervous system lymphomas are derived from germinal-center B-cells and show a preferential Usage of the V4-34 gene segment
58. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B-cells with ongoing mutational activity
59. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens
60. B-cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions